In the context of bilateral nephrectomy, rosuvastatin acts on these hypoxia-inducible factors across various organs and tissues, offering a strategic approach to anemia management by promoting erythropoietin synthesis outside the kidneys [50,51,54]. The gene discussed is EPO; the disease is anemia.